Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

183. CORTIMENT (budesonide), corticosteroid for local use

CORTIMENT (budesonide), corticosteroid for local use Haute Autorité de Santé - CORTIMENT (budésonide), corticoïde d’action locale Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments CORTIMENT (budésonide), corticoïde d’action locale Substance active (DCI) budésonide GASTRO-ENTEROLOGIE - Nouveau médicament Nature de la demande Inscription Avis de

2017 Haute Autorite de sante

184. Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality

Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality Antenatal corticosteroid administration between 24 hours and 7 days before extremely preterm delivery is associated with the lowest rate of mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Antenatal corticosteroid administration between 24 hours and 7 days before extremely

2017 Evidence-Based Medicine (Requires free registration)

185. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids Article Text Commentary General medicine In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

2017 Evidence-Based Medicine (Requires free registration)

186. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I)

Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I) Guidelines for the Diagnosis and Management of Critical Illn... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me (...) Note Procite Reference Manager Save my selection doi: 10.1097/CCM.0000000000002737 Special Articles Free Objective: To update the 2008 consensus statements for the diagnosis and management of critical illness -related corticosteroid insufficiency (CIRCI) in adult and pediatric patients. Participants: A multispecialty task force of 16 international experts in critical care medicine, endocrinology, and guideline methods, all of them members of the Society of Critical Care Medicine and/or the European

2017 Society of Critical Care Medicine

187. Antenatal Corticosteroid Therapy for Fetal Maturation

Antenatal Corticosteroid Therapy for Fetal Maturation Antenatal Corticosteroid Therapy for Fetal Maturation - ACOG Menu ▼ Antenatal Corticosteroid Therapy for Fetal Maturation Page Navigation ▼ INTERIM UPDATE A correction was published in November 2017 for this title. Click to view the correction. Number 713, August 2017 (Replaces Committee Opinion No. 677, October 2016) (Reaffirmed 2018) Committee on Obstetric Practice This Committee Opinion was developed by the American College (...) , or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented. INTERIM UPDATE: This Committee Opinion is updated as highlighted to reflect a limited focused change to clarify that, among specific populations, antenatal corticosteroids should be administered when a woman is at risk of preterm delivery within 7 days. Antenatal

2017 American College of Obstetricians and Gynecologists

188. Allergic Rhinitis - Guidelines for Prescribing Intranasal Corticosteroids

Allergic Rhinitis - Guidelines for Prescribing Intranasal Corticosteroids Allergic Rhinitis - Guidelines for Prescribing Intranasal Corticosteroids - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Allergic Rhinitis - Guidelines for Prescribing Intranasal Corticosteroids An inflammatory disorder of the nose which occurs when the membranes lining the nose become sensitized to allergens. Mediated by immunoglobulin E (IgE (...) , antihistamines can be administered as prophylaxis 2 - 5 hours prior to exposure. Decongestants Oral and nasal decongestants are effective in reducing AR-induced nasal congestion. Can be used in combination with antihistamine and intranasal corticosteroids. Long-term use may be required in AR so intranasal decongestants are generally not recommended. If used, limit duration to 3 - 7 days to prevent rebound congestion. Avoid use in children under 6. Mast-Cell Stabilizer Sodium cromoglycate - less effective

2017 medSask

189. Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids (Full text)

Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Chronic, recurring, inflammatory disorder of the skin. Often referred to as eczema, but they are not interchangeable terms: Eczema is a group of skin conditions, which (...) appropriate. Symptoms are interfering with quality of life and sleep Nummular discoid eczema - small round plaques of small papules and blisters, usually on trunk or extremities - recommended treatment is potent topical corticosteroids. Large areas of skin are involved (> 30 % of body surface area) - risk of systemic absorption of corticosteroid if large areas of skin are being treated. Pediatric patients may be at higher risk of topical corticosteroid-induced HPA axis suppression and Cushing's syndrome

2017 medSask PubMed

190. Is there benefit adding antivirals to corticosteroids for BellÂ’s palsy in adults? (Full text)

Is there benefit adding antivirals to corticosteroids for BellÂ’s palsy in adults? Bell’s palsy is the first cause of unilateral facial palsy. The likely etiologic mechanism is facial nerve inflammation secondary to viral reactivation, most probably due to herpes simplex and Varicella Zoster. Corticosteroids are considered the mainstay of treatment, but it is not clear whether adding antivirals would further increase the benefit. Searching in Epistemonikos database, which is maintained (...) by screening 30 databases, we identified 10 systematic reviews including 15 pertinent randomized controlled trials overall. We combined the evidence and generated a summary of findings following the GRADE approach. We concluded that adding antivirals to the treatment with corticosteroids probably reduces the risk of incomplete recovery in patients with Bell’s palsy.

2016 Medwave PubMed

191. Intra-articular Corticosteroids for Osteoarthritis of the Knee. (Full text)

Intra-articular Corticosteroids for Osteoarthritis of the Knee. Are intra-articular corticosteroids associated with improvement in pain and physical function compared with sham injection or no intervention in patients with knee osteoarthritis?Intra-articular corticosteroids may be associated with moderate improvement in pain and a small improvement in physical function up to 6 weeks after injection. However, the quality of the evidence is low.

2016 JAMA PubMed

192. Long-term topical corticosteroid use and risk of skin cancer: a systematic review protocol. (Full text)

Long-term topical corticosteroid use and risk of skin cancer: a systematic review protocol. The objective of this systematic review is to synthesize the best available research evidence to determine the risk of skin cancer in patients on long-term use of topical corticosteroids. Specifically the review question is: In people using long-term (regular use over one month) topical corticosteroids, what is the risk of developing skin cancer (clinically or histologically confirmed basal cell

2016 JBI database of systematic reviews and implementation reports PubMed

193. Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids (Full text)

Juvenile X-linked retinoschisis responsive to intravitreal corticosteroids To report the case of an adult male with X-linked retinoschisis (XLRS) who presented with cystoid macular edema (CME) that responded consistently to treatment with intravitreal steroids.A 39 year old male with unilateral presentation of CME after repair of a retinal detachment secondary to XLRS responded initially to an injection of intravitreal triamcinolone acetonide (IVTA). Central subfield thickness on OCT (...) related to XLRS. Here, we document a case of a man who successfully had decrease of intraretinal fluid and schisis with treatment of intravitreal corticosteroids as demonstrated by spectral domain optical coherence tomography.

2016 American journal of ophthalmology case reports PubMed

194. Do corticosteroid injections improve carpal tunnel syndrome symptoms?

Do corticosteroid injections improve carpal tunnel syndrome symptoms? Do corticosteroid injections improve carpal tunnel syndrome symptoms? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do corticosteroid injections improve carpal tunnel syndrome symptoms? View/ Open Date 2016-02 Format Metadata Abstract Q: Do (...) corticosteroid injections improve carpal tunnel syndrome symptoms? Evidence-based answer: Yes. injected corticosteroids reduce symptoms of carpal tunnel syndrome (CTS) more effectively than placebo or systemic steroids, but no better than anti-inflammatory medication and splinting, from one to 12 weeks after therapy (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and consistent RCT). A 40-mg injection of methylprednisolone reduces symptoms as effectively as an 80-mg

2016 Clinical Inquiries

195. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. (PubMed)

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Low-dose inhaled corticosteroids (ICS) are highly effective for reducing asthma exacerbations and mortality. Conventionally, ICS treatment is recommended for patients with symptoms on more than 2 days per week, but this criterion has scant evidence. We aimed to assess the validity of the previous symptom-based cutoff for starting (...) corticosteroids were randomised to receive once daily, inhaled budesonide 400 μg (those aged <11 years 200 μg) or placebo. Coprimary outcomes for this analysis were time to first severe asthma-related event (SARE; hospital admission, emergency treatment, or death) and change from baseline in lung function after bronchodilator. Interaction with baseline symptom frequency was investigated, with patients grouped by more than two symptom days per week and two or fewer symptom days per week (divided into no days

2016 Lancet

196. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. (Full text)

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and updated in 2013 and 2016.To assess the effects of pharmacological agents other than plasma exchange, intravenous immunoglobulin (...) and corticosteroids for GBS.On 18 January 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for treatments for GBS. We also searched clinical trials registries.We included all randomised controlled trials (RCTs) or quasi-RCTs of acute GBS (within four weeks from onset) of all types and degrees of severity, and in individuals of all ages. We discarded trials that investigated only corticosteroids, intravenous immunoglobulin

2016 Cochrane PubMed

197. Inhaled corticosteroids with combination inhaled long-acting beta<sub>2</sub>-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. (Full text)

Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease (COPD) commonly involves long-acting bronchodilators including beta-agonists (LABA) and muscarinic antagonists (LAMA). In individuals with persistent symptoms or frequent exacerbations, inhaled corticosteroids (ICS) are also used. LABA and LAMA bronchodilators are now available (...) in single combination inhalers. However, the benefits and risks of adding ICS to combination LABA/LAMA inhalers remains unclear.To assess the effect of adding an inhaled corticosteroid (ICS) to combination long-acting beta₂-agonist (LABA)/long-acting muscarinic antagonist (LAMA) inhalers for the treatment of stable COPD.We carried out searches using the Cochrane Airways Group Specialised Register of Trials (searched 20 September 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue

2016 Cochrane PubMed

198. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. (Full text)

Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. Anakinra, an interleukin 1β recombinant receptor antagonist, may have potential to treat colchicine-resistant and corticosteroid-dependent recurrent pericarditis.To determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis.The Anakinra-Treatment of Recurrent Idiopathic Pericarditis (...) (AIRTRIP) double-blind, placebo-controlled, randomized withdrawal trial (open label with anakinra followed by a double-blind withdrawal step with anakinra or placebo until recurrent pericarditis occurred) conducted among 21 consecutive patients enrolled at 3 Italian referral centers between June and November 2014 (end of follow-up, October 2015). Included patients had recurrent pericarditis (with ≥3 previous recurrences), elevation of C-reactive protein, colchicine resistance, and corticosteroid

2016 JAMA PubMed

199. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis

Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis A number of corticosteroid minimization and avoidance protocols for post-solid organ transplant have been developed. The study objective was to examine the effect of corticosteroid withdrawal/avoidance on growth and safety parameters in pediatric solid organ transplant recipients.A systematic review using Medline and Embase was performed. All randomized controlled trials (RCT (...) ) and observational studies comparing corticosteroid withdrawal/avoidance to controls receiving corticosteroids in pediatric transplant recipients which reported growth as change in height or final height were included. Two reviewers independently abstracted study data and assessed quality.The search yielded 930 records, 14 separate studies involving 1146 patients. Renal RCTs (n = 5) showed that corticosteroid withdrawal/avoidance was associated with a significant increase in growth (mean difference in height

2016 EvidenceUpdates

200. Mid-Childhood Outcomes of Repeat Antenatal Corticosteroids: A Randomized Controlled Trial (Full text)

Mid-Childhood Outcomes of Repeat Antenatal Corticosteroids: A Randomized Controlled Trial To assess if exposure to repeat dose(s) of antenatal corticosteroids has beneficial effects on neurodevelopment and general health in mid-childhood, at 6 to 8 years' corrected age.Women at risk for very preterm birth, who had received a course of corticosteroids ≥7 days previously, were randomized to intramuscular betamethasone (11.4 mg Celestone Chronodose) or saline placebo, repeated weekly if risk (...) of very preterm birth remained. Mid-childhood assessments included neurocognitive function, behavior, growth, lung function, blood pressure, health-related quality of life, and health service utilization. The primary outcome was survival free of neurosensory disability.Of the 1059 eligible long-term survivors, 963 (91%) were included in the primary outcome; 479 (91%) in the repeat corticosteroid group and 484 (91%) in the placebo group. The rate of survival free of neurosensory disability was similar

2016 EvidenceUpdates PubMed